Jazz Pharmaceuticals (JAZZ) Share-based Compensation (2010 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Share-based Compensation of $74.5 million for Q1 2026, up 10.04% year-over-year from $67.7 million in Q1 2025, and up 5.15% quarter-over-quarter from $70.9 million in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Share-based Compensation (2010 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Share-based Compensation history runs 17 years deep, the most recent figure standing at $74.5 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 10.04% year-over-year to $74.5 million; the TTM figure through Mar 2026 stood at $297.9 million (up 365.43% YoY), while the FY2025 annual figure was $291.1 million, up 404.1% from the prior year.
- Share-based Compensation for Q1 2026 stood at $74.5 million, up from $70.9 million in the prior quarter.
- The five-year high for Share-based Compensation was $150.9 million in Q3 2025, with the low at -$115.0 million in Q4 2022.
- The 5-year median for Share-based Compensation is $56.4 million (2023), against an average of $40.9 million.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation tumbled 395.31% in 2022, then jumped 1669.14% in 2025.
- Jazz Pharmaceuticals' Share-based Compensation stood at -$115.0 million in 2022, then jumped by 146.04% to $52.9 million in 2023, then plunged by 92.43% to $4.0 million in 2024, then surged by 1669.14% to $70.9 million in 2025, then grew by 5.15% to $74.5 million in 2026.
- Business Quant data shows JAZZ's Share-based Compensation at $74.5 million in Q1 2026, $70.9 million in Q4 2025, and $150.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn | 44.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44.20 Mn |
| Jun 30, 2026 | 44.20 Mn |
| Mar 31, 2026 | 74.50 Mn |
| Mar 31, 2026 | 74.50 Mn |
| Dec 31, 2025 | 70.85 Mn |
| Dec 31, 2025 | 70.85 Mn |
| Sep 30, 2025 | 150.87 Mn |
| Sep 30, 2025 | 150.87 Mn |
| Jun 30, 2025 | 1.71 Mn |
| Jun 30, 2025 | 1.71 Mn |
| Mar 31, 2025 | 67.70 Mn |
| Mar 31, 2025 | 67.70 Mn |
| Dec 31, 2024 | 4.01 Mn |
| Dec 31, 2024 | 4.01 Mn |
| Sep 30, 2024 | -64.35 Mn |
| Sep 30, 2024 | -64.35 Mn |
| Jun 30, 2024 | 56.65 Mn |
| Jun 30, 2024 | 56.65 Mn |
| Mar 31, 2024 | 61.44 Mn |
| Mar 31, 2024 | 61.44 Mn |